HIV prevention shot delivery: which clinic strategy works best?
NCT ID NCT05374525
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This study looked at two different strategies for giving cabotegravir, a long-acting HIV prevention shot, to HIV-negative men who have sex with men and transgender men in U.S. clinics. About 287 participants received the shot either after a month of pills or directly as injections. Researchers measured how easy it was for clinic staff to offer the shot in both low- and high-volume settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Los Angeles, California, 90036, United States
-
GSK Investigational Site
San Francisco, California, 94102, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20005, United States
-
GSK Investigational Site
Miami, Florida, 33140, United States
-
GSK Investigational Site
Orlando, Florida, 32806, United States
-
GSK Investigational Site
Pensacola, Florida, 32503, United States
-
GSK Investigational Site
Sarasota, Florida, 34237, United States
-
GSK Investigational Site
Bridgeport, Kansas, 06605, United States
-
GSK Investigational Site
Boston, Massachusetts, 02215, United States
-
GSK Investigational Site
Columbia, Missouri, 65212, United States
-
GSK Investigational Site
St Louis, Missouri, 63117, United States
-
GSK Investigational Site
Rochester, New York, 14607, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19123, United States
-
GSK Investigational Site
Charleston, South Carolina, 29407, United States
-
GSK Investigational Site
Harlingen, Texas, 78550, United States
-
GSK Investigational Site
Seattle, Washington, 98104, United States
Conditions
Explore the condition pages connected to this study.